Paolo Verdecchia
Overview
Explore the profile of Paolo Verdecchia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
361
Citations
6331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zappa M, Golino M, Verdecchia P, Angeli F
J Cardiovasc Dev Dis
. 2024 May;
11(5).
PMID: 38786976
Arterial hypertension is the most frequent cardiovascular risk factor all over the world, and it is one of the leading drivers of the risk of cardiovascular events and death. It...
12.
Angeli F, Verdecchia P, Reboldi G
Eur J Intern Med
. 2024 Apr;
126:83-88.
PMID: 38616483
Background: Most Hypertension Guidelines grade hypertension according to various cut-off values. We sought to investigate the prognostic impact of Grades 1 (140-159 and/or 90-99 mmHg), 2 (160-179 and/or 100-109 mmHg)...
13.
DElia L, Masulli M, Cirillo P, Virdis A, Casiglia E, Tikhonoff V, et al.
Metabolites
. 2024 Mar;
14(3).
PMID: 38535324
Several studies have detected a direct association between serum uric acid (SUA) and cardiovascular (CV) risk. In consideration that SUA largely depends on kidney function, some studies explored the role...
14.
Angeli F, Verdecchia P, Coiro S, Santucci A, Notaristefano F, Bartolini C, et al.
G Ital Cardiol (Rome)
. 2024 Mar;
25(4):262-269.
PMID: 38526362
Superiority trials are designed to test the hypothesis that a given diagnostic or therapeutic strategy is better than (i.e. "superior to") placebo or an active control. Conversely, non-inferiority trials test...
15.
DElia L, Masulli M, Virdis A, Casiglia E, Tikhonoff V, Angeli F, et al.
J Clin Endocrinol Metab
. 2024 Mar;
110(2):e470-e477.
PMID: 38482609
Purpose: Recently, a novel index [the triglyceride-glucose (TyG) index]) was considered a surrogate marker of insulin resistance (IR); in addition, it was estimated to be a better expression of IR...
16.
Tikhonoff V, Casiglia E, Virdis A, Grassi G, Angeli F, Arca M, et al.
J Am Heart Assoc
. 2024 Jan;
13(3):e030319.
PMID: 38293920
Background: Despite longstanding epidemiologic data on the association between increased serum triglycerides and cardiovascular events, the exact level at which risk begins to rise is unclear. The Working Group on...
17.
Verdecchia P, Angeli F, Reboldi G
Eur J Intern Med
. 2024 Jan;
123:42-48.
PMID: 38278661
The optimal blood pressure (BP) target for prevention of cardiovascular complications of hypertension remains uncertain. Most Guidelines suggest different targets depending on age, comorbidities and treatment tolerability, but the underlying...
18.
Coiro S, Verdecchia P, Angeli F
Eur J Intern Med
. 2023 Nov;
120:29-31.
PMID: 38016904
No abstract available.
19.
Angeli F, Zappa M, Bartolini C, Verdecchia P
G Ital Cardiol (Rome)
. 2023 Nov;
24(12):948-950.
PMID: 38009345
No abstract available.
20.
Angeli F, Zappa M, Verdecchia P
Eur J Intern Med
. 2023 Oct;
118:32-35.
PMID: 37891024
No abstract available.